Boyer Jennifer Yi Sells 10,938 Shares of Inogen (NASDAQ:INGN) Stock

Inogen, Inc (NASDAQ:INGN) EVP Boyer Jennifer Yi sold 10,938 shares of the firm’s stock in a transaction that occurred on Wednesday, July 1st. The shares were sold at an average price of $6.60, for a total transaction of $72,190.80. Following the completion of the transaction, the executive vice president owned 5,039 shares in the company, valued at $33,257.40. The trade was a 68.46% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

Inogen Stock Down 1.9%

INGN opened at $6.54 on Wednesday. Inogen, Inc has a 52-week low of $5.34 and a 52-week high of $9.13. The company has a 50 day moving average of $6.59 and a two-hundred day moving average of $6.41. The company has a market cap of $177.07 million, a P/E ratio of -7.19 and a beta of 1.58.

Inogen (NASDAQ:INGN) last posted its earnings results on Thursday, May 7th. The medical technology company reported ($0.30) earnings per share for the quarter, missing the consensus estimate of ($0.24) by ($0.06). Inogen had a negative net margin of 7.08% and a negative return on equity of 12.90%. The business had revenue of $85.11 million for the quarter, compared to analyst estimates of $82.35 million. Research analysts anticipate that Inogen, Inc will post -0.77 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Inogen in a research report on Friday, May 8th. Freedom Capital upgraded shares of Inogen to a “strong-buy” rating in a research note on Tuesday, April 7th. One equities research analyst has rated the stock with a Strong Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy”.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Armistice Capital LLC raised its holdings in Inogen by 46.3% in the fourth quarter. Armistice Capital LLC now owns 1,264,000 shares of the medical technology company’s stock valued at $8,494,000 after acquiring an additional 400,000 shares in the last quarter. Arrowstreet Capital Limited Partnership grew its holdings in Inogen by 203.9% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 586,159 shares of the medical technology company’s stock worth $3,622,000 after acquiring an additional 393,310 shares in the last quarter. CSM Advisors LLC bought a new stake in shares of Inogen in the 3rd quarter worth about $2,973,000. Goldman Sachs Group Inc. increased its position in shares of Inogen by 37.6% in the 4th quarter. Goldman Sachs Group Inc. now owns 589,273 shares of the medical technology company’s stock worth $3,960,000 after purchasing an additional 160,960 shares during the last quarter. Finally, AQR Capital Management LLC raised its stake in shares of Inogen by 30.1% in the 1st quarter. AQR Capital Management LLC now owns 564,032 shares of the medical technology company’s stock valued at $4,022,000 after purchasing an additional 130,381 shares in the last quarter. Hedge funds and other institutional investors own 89.94% of the company’s stock.

Inogen Company Profile

Inogen, Inc (NASDAQ: INGN) is a medical device company specializing in the development, manufacture and marketing of innovative oxygen therapy solutions. The company’s core focus is on portable oxygen concentrators (POCs) designed to support patients with chronic respiratory conditions such as chronic obstructive pulmonary disease (COPD). Inogen’s offerings aim to provide users with mobility and independence by reducing reliance on traditional compressed-gas cylinders and enabling oxygen therapy on the go.

Inogen’s flagship product line, including the Inogen One family of portable oxygen concentrators, leverages proprietary flow technology to deliver continuous and pulse-dose oxygen.